The share price of USA-based Aradigm (Nasdaq: ARDM) collapsed on Thursday after the company announced top-line results from its two Phase III trials of Pulmaquin (ciprofloxacin).
Pulmaquin is Aradigm’s investigational proprietary formulation of once-daily ciprofloxacin for inhalation, in patients with non-cystic fibrosis bronchiectasis (non-CF BE) with chronic lung infections with Pseudomonas aeruginosa (P aeruginosa).
In 2013, Aradigm granted an exclusive, worldwide license for the company's inhaled liposomal ciprofloxacin product candidates for the indication of non-CF BE and other indications to Grifols (GRF: MC), and the Spanish drugmaker's share price had also dropped by nearly 4% by Friday afternoon compared to its closing price on Wednesday, following the announcement of the trial results.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze